American pharmaceutical company
Vertex acquires Alpine Immune Sciences: The Boston-based drug company is acquiring Alpine Immune Sciences, a developer of immunotherapies, for $65 a share.
bostonglobe.com/2024/04/10/business/vertex-alpine-immune-sciences-acquisition/
Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune: Vertex Pharmaceuticals announced a $4.9 billion deal to buy Alpine Immune ...
barrons.com/articles/vertex-pharmaceuticals-stock-alpine-immune-deal-a3a27f8e
Paid articlePaid
These Stocks Are Moving the Most Today: Alpine Immune, Regeneron, Costco, Constellation Brands, CarMax, and More
barrons.com/articles/stock-market-movers-7f0a8161
Paid articlePaid
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers
apnews.com/article/vertex-pharmaceuticals-pain-drug-opioid-medication-study-5ec38713f486ccbab827b7dd04aa8484
Improving Care for Idiopathic Hypersomnia: Patient and Clinician Perspectives : The impact of hypersomnia on the patient’s quality of life and how clinicians can ...
medscape.org/viewarticle/1000417
Vertex scientists' Breakthrough Prize draws protest over drug pricing: The controversy threatened to mar a celebrity-studded celebration for researchers who ...
bostonglobe.com/2024/04/11/business/vertex-breakthrough-awards-cystic-fibrosis/
Vertex mulling HQ move from Fan Pier to new digs in the Seaport: The life science giant is mulling a more consolidated campus in the outer Seaport.
bostonglobe.com/2024/03/25/business/vertex-headquarters-seaport/
Vertex Pharmaceuticals Incorporated (VRTX) Leerink Partners Global Biopharma Conference (Transcript)
seekingalpha.com/article/4677486-vertex-pharmaceuticals-incorporated-vrtx-leerink-partners-global-biopharma-conference
The World's Most Innovative Companies of 2024: Fast Company's 2024 ranking of the World's Most Innovative Companies features Nvidia at No ...
fastcompany.com/most-innovative-companies/list
Vertex Is the Last Good Place Online: Completing a game of Vertex takes just 15 minutes, but I’ve started calling that time my smooth-brain hours.
wired.com/story/last-good-place-vertex/
South Africans take on big pharma for access to ‘miracle’ cystic fibrosis drug: Cheri Nel cannot afford Vertex’s Trikafta medicine, so she is suing to end ...
theguardian.com/global-development/2024/mar/18/cystic-fibrosis-patient-south-africa-cheri-nel-lawsuit-big-pharma-generic-drugs-trikafta-access-vertex
Connections is a daily game about finding common threads between words. Players must select four groups of four words without making more than four mistakes ... Show more nyti.ms/3OXxSgp
How did you do in Connections today? Players must select four groups of four words without making more than four mistakes. nyti.ms/49j8tpj Show more
Crispr Reports Its First Profit In 10 Quarters; But Shares Reverse Lower: Crispr Therapeutics reported its first profit in 10 quarters on Wednesday ...
investors.com/news/technology/crsp-stock-flies-out-of-a-buy-zone-after-crispr-reports-its-first-profit-in-10-quarters/
Starting today: The Globe's second-annual Health & Biotech Week is a virtual series highlighting developments happening here that will have global impact ... Show more trib.al/HBnrPVT
Vertex's triple combination CF treatment meets main late-stage trial goals: Vertex Pharmaceuticals' experimental triple combination cystic fibrosis (CF) ...
reut.rs/3SLUaUq
Vertex Pharmaceuticals Incorporated 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com/article/4667643-vertex-pharmaceuticals-incorporated-2023-q4-results-earnings-call-presentation
Paid articlePaid Connections is a daily game about finding common threads between words.
Players must select four groups of four words without making more than four mistakes ... Show more nyti.ms/3I20bWR
How did you do in Connections today? Players must select four groups of four words without making more than four mistakes. nyti.ms/3ukg8EZ Show more
Non-opioid proves effective for acute surgical & non-surgical pain: A series of Phase 3 clinical trials into a novel oral, non-opioid painkiller has found that ...
newatlas.com/medical/phase-3-clinical-trials-non-opioid-sodium-channel-blocker-acute-pain/
Vertex Experimental Drug Cuts Off Pain at the Source, Company Says: Vertex Pharmaceuticals said its medicine could address moderate to severe acute pain ...
nytimes.com/2024/01/30/health/vertex-pain-medicine-non-opioid.html
Connections is a daily game about finding common threads between words.
Players must select four groups of four words without making more than four mistakes ... Show more nyti.ms/3w19LXn
Vertex Unveils Strong Data on Opioid Alternative: If approved, it would be the first new pain medicine in decades, and could provide an alternative to opioids.
barrons.com/articles/vertex-opioid-alternative-d726a852
Paid articlePaid How did you do in Connections today?
Players must select four groups of four words without making more than four mistakes. Play here: nyti.ms/42bVljn Show more
FDA Approves New CRISPR Gene-Editing Treatment: The Food and Drug Administration approved the use of Casgevy, a CRISPR gene-editing therapy ...
forbes.com/sites/jamesfarrell/2024/01/16/fda-approves-new-crispr-gene-editing-treatment/
Vertex's Non-Opioid Painkiller Is Just What America Needs: Policymakers should encourage doctors to prescribe and health insurers to cover pain pills that ...
bloomberg.com/opinion/articles/2024-02-03/vertex-s-non-opioid-painkiller-is-just-what-america-needs
How did you do in Connections today? Today’s difficulty is 3.2 out of five. nyti.ms/3OfpLv5 Show more
Alkeus says its eye therapy halts progression of genetic disease: Privately held Alkeus Pharmaceuticals said on Wednesday its experimental therapy halted disease ...
reuters.com/business/healthcare-pharmaceuticals/alkeus-says-its-eye-therapy-halts-progression-genetic-disease-2024-01-10/
How did you do in Connections today? Players must select four groups of four words without making more than four mistakes. nyti.ms/48Nl2t7 Show more
Thomson Reuters offers to buy Sweden's Pagero for $627 mln: Thomson Reuters (TRI.TO) said on Thursday it has offered to buy Swedish e-invoicing and tax solutions ...
reuters.com/markets/deals/thomson-reuters-offers-buy-swedens-pagero-627-mln-2024-01-11/
How did you do in Connections today? Players must select four groups of four words without making more than four mistakes. Show more
Vertex Pauses Islet Cell Study After Patient Deaths: The deaths are unrelated to the investigational allogeneic stem cell–derived product VX-880 ...
medscape.com/viewarticle/vertex-pauses-islet-cell-study-after-patient-deaths-2024a10000oe
Expensive Drugs From Big US Pharma Get More Money From FDA Program: Big Pharma is cashing in on FDA vouchers at the expense of smaller companies and nonprofits.
bloomberg.com/news/articles/2023-12-21/expensive-drugs-from-big-us-pharma-get-more-money-from-fda-program
Paid articlePaid How did you do in Connections today?
Players must select four groups of four words without making more than four mistakes. Show more
How did you do in Connections today?
Players must select four groups of four words without making more than four mistakes. t.co/VFGBhXsDEk Show more
Vertex, IBD Stock Of The Day, Called 'Underappreciated Winner' For 2024
investors.com/research/ibd-stock-of-the-day/verx-stock-called-underappreciated-winner/
Subscribe to New York Times Games: Upgrade your downtime with full access to The Crossword, The Mini, Spelling Bee and more.
nytimes.com/crosswords
Bluebird Bio Stock Is in Freefall Weeks After a Landmark FDA Approval. Here’s Why.
barrons.com/articles/bluebird-bio-stock-offering-price-down-93fde066
Paid articlePaid "Popular TikTok character" was the hardest Crossword clue this year. Did you get the answer?
Play here:
Play The Crossword: Keep your mind sharp by making The Crossword part of your daily routine.
nytimes.com/crosswords/game/daily/2023/05/10
Google’s Hugging Face deal puts ‘supercomputer’ power behind open-source AI: A new partnership between Hugging Face and Google Cloud will give open-source AI ...
theverge.com/2024/1/25/24050445/google-cloud-hugging-face-ai-developer-access
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
cnbc.com/2023/12/28/investors-see-a-biotech-comeback-in-2024-as-rates-fall-dealmaking-picks-up-stocks-to-watch-.html
Paid articlePaid F.D.A. Approves 2 Sickle Cell Treatments, One Using CRISPR Gene Editing: People with the genetic disease have new opportunities to eliminate their symptoms ...
nytimes.com/2023/12/08/health/fda-sickle-cell-crispr.html
Quick Glance: FDA Approves Gene-Editing Treatment for Sickle Cell
- The FDA approved two gene therapies for severe sickle cell, a milestone for treatment and gene therapy.
- The therapy uses CRISPR technique to infuse modified cells back into patients and was developed by Vertex Pharmaceuticals and CRISPR Therapeutics.
- While the approvals are celebrated, concerns exist that the treatments may not be accessible to all patients.
- Gene editing is being studied as a treatment for various diseases, from rare genetic disorders to common ailments like cancer, heart disease, diabetes, AIDS, and Alzheimer's.
FDA Approves First Two Sickle Cell Gene Therapies: The Food and Drug Administration on Friday approved two gene therapies to treat patients with sickle cell ...
barrons.com/articles/fda-sickle-cell-crispr-vertex-bluebird-stock-price-baabeaa5
Paid articlePaid
Eli Lilly, Vertex, Merck & Co: Big deals expected: More and more large pharmaceutical and biotech companies are looking for promising acquisitions in order to ...
deraktionaer.de/artikel/pharma-biotech/eli-lilly-vertex-merck-co-grosse-deals-erwartet-20348188.html
Omoda E5 teased at Motor Show, showroom to be ready by March: The pint-sized Chery QQ is perhaps what most Singaporeans (of a certain age) have associated with ...
asiaone.com/lifestyle/omoda-e5-teased-motor-show-showroom-be-ready-march
Cystic fibrosis: The miracle drugs priced out of reach: Regulators around the world have questioned the high price set by Vertex Pharmaceuticals.
bbc.com/news/health-67712269
Vertex's non-opioid drug reduces nerve pain in trial, shares hit record high
reuters.com/business/healthcare-pharmaceuticals/vertexs-neuropathic-pain-treatment-succeeds-mid-stage-trial-2023-12-13/
Vertex's stock rallies on experimental pain pill trial results: Vertex wants to interrupt pain signals before they reach the brain, and because its non-opioid ...
bostonglobe.com/2023/12/23/business/vertex-experimental-non-opioid-pain-pill/
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most: There is no clear path for African patients to get access to the treatments ...
nytimes.com/2023/12/08/health/casgevy-lyfgenia-sickle-cell-africa.html
How did you do in Connections today? Players must select four groups of four words without making more than four mistakes. Show more
Vertex Stock Jumps on Hope for a Pain-Pill Blockbuster: Vertex disclosed promising test results for a drug that could offer an alternative to opioids.
barrons.com/articles/vertex-stock-trial-pain-pill-blockbuster-26f19dd1
Paid articlePaid BBH: A Solid Way To Play A Comeback In Biotech: Consider the potential outperformance of the biotech sector in the next year with VanEck Biotech ETF (BBH) ...
seekingalpha.com/article/4657022-bbh-solid-way-comeback-biotech
Paid articlePaid Vertex Stock Is Down. Its Painkiller Could Spark Big Gains.: Disappointment about the construction of a drug trial has caused Vertex stock to fall ...
barrons.com/articles/vertex-stock-price-painkillers-0e8dd4d1
Paid articlePaid
Google's Gemini AI model is now available for companies to use: Gemini, Google's rival to OpenAI's ChatGPT, is now available for companies to use ...
businessinsider.com/gemini-ai-google-search-company-internal-data-chatgpt-competitor-2023-12
Quick Glance: Victory for Epic Games in Antitrust Lawsuit Against Google
- Court ruling confirms antitrust barriers in the Google Android App Store.
- The unanimous decision came after brief deliberation.
- Epic Games filed the lawsuit three years ago and was unanimously decided in favor of Epic Games.
The lucky break behind the first CRISPR treatment: Gene editing for sickle-cell is here. This is how researchers knew what DNA to change.
technologyreview.com/2023/12/07/1084629/lucky-break-crispr-vertex/
Reinforcement learning helping fine-tune Gemini Pro, says Google Cloud CEO: Gemini Pro is now available for developers and organisations. The Alphabet Inc ...
indianexpress.com/article/technology/artificial-intelligence/gemini-pro-api-google-cloud-ceo-duetai-9066745/
Vertex Pharmaceuticals: A Full Pipeline: Vertex Pharmaceuticals released data validating the efficacy and safety of their NaV1.8 inhibitor for chronic ...
seekingalpha.com/article/4661542-vertex-pharmaceuticals-a-full-pipeline
Paid articlePaid
2023 was a big year for CRISPR-based gene editing but challenges remain: 2023 was an important year for patients with sickle cell disease. The FDA approved ...
engt.co/3thTKvn
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
cnbc.com/2023/12/07/crispr-gene-editing-treatment-us-approval.html
Vertex will pay tens of millions to license a controversial CRISPR patent: The company will pay rival Editas Medicine and the Broad Institute so that it can sell ...
technologyreview.com/2023/12/13/1085209/vertex-license-controversial-crispr-patent-editas/
Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.: Things could hardly have gone worse for healthcare investors in 2023. While shares of Eli Lilly ...
barrons.com/articles/healthcare-stocks-2024-outlook-biotech-medtech-pharma-1df0071e
Paid articlePaid
Cystic fibrosis patients could see 'miracle drug' cut from NHS due to 'unjustifiable' costs
itv.com/news/2023-11-23/cystic-fibrosis-miracle-drug-may-be-cut-from-nhs-due-to-costs
Editas Medicine: Assessing The Impact Of Casgevy And Lyfgenia Approvals: Editas Therapeutics is developing a gene-editing therapy called reni-cel for Sickle Cell ...
seekingalpha.com/article/4659592-editas-medicine-assessing-impact-casgevy-lyfgenia-approvals
Paid articlePaid In a first for Singapore, livestreaming app 17LIVE goes public via SPAC merger: Shares of Asian livestreaming app 17LIVE began trading on Friday following merger ...
cnbc.com/2023/12/08/17live-goes-public-via-singapores-first-spac-merger.html
Gene editing had a banner year in 2023: This year, gene editing finally started living up to its potential
technologyreview.com/2023/12/22/1085809/gene-editing-had-a-banner-year-in-2023/
Vertex sickle cell drug approved in UK: The go-ahead comes about two weeks before the FDA is set to determine whether CRISPR and Boston-based Vertex can market ...
bostonglobe.com/2023/11/16/business/vertex-sickle-cell-crispr-fda/
Google makes Gemini Pro available in AI Studio, Vertex AI tools: Google's Duet AI tool also becomes generally available and will get Gemini access 'over the next ...
zdnet.com/article/google-makes-gemini-pro-available-in-ai-studio-vertex-ai-tools/
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics